Abstract: A compound comprising a first ligand LA of Formula I, is provided. In Formula I, moiety C is a monocyclic ring or fused polycyclic system; each of X1 to X6 is C or N; K is a direct bond or a linker; at least one of RB or RC has the formula -L-SiR1R2R3, or -L-GeR1R2R3; L is a direct bond or an organic linker; each R?, R?, R1, R2, R3, RA, RB, and RC is hydrogen or a General Substituent defined herein; LA is coordinated to a metal M by the dashed lines in Formula I; and M has an atomic mass of at least 40 and may be coordinated to other ligands. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: Provided are compounds of Formula Ir(LA)x(LC)y wherein: ligand LA has Formula I? ?and ligand LC has Formula II?

Abstract: A compound comprising a first ligand LX comprising a structure of Formula IV, In Formula IV, ring F is a 5- or 6-membered ring; Z3, A1, A2, and A3 are C or N; A4 is C and ring F bonds to ring I at A4; n is 0 or 1; two adjacent atoms of A5 to A8 are C; adjacent substituents selected from RH and RI join or fuse together to form at least two fused heterocyclic or carbocyclic rings; Y is a linking group; and LX is complexed to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of formula Ir(LA)x(LB)y(LC)z, where the a first ligand LA has a structure of Formula I, is provided. In Formula I, moiety A is a monocyclic ring; each of X1 to X10 and Z1 is C or N; K1 and K2 are each a direct bond or a linker; each R?, R?, RA and RB is hydrogen or a General Substituent defined herein; LB and LC are bidentate ligands; x=1, 2, or 3, y and z are each 0, 1, or 2, and x+y+z=3. Formulations, OLEDs, and consumer products comprising the compound are also provided.

Abstract: A compound comprising a ligand LA of Formula I, where G has a structure of is disclosed. In ligand LA, Ring C is a 5-membered or 6-membered ring; K is a direct bond, O, or S; when K is O or S, X6 is C; each of RA, RB, and RC is H or a substituent, and can be joined together to form a ring; each of X1 to X6 is independently C or N; X1 is C if it is connected to ring C; the RB substituents of at least two adjacent ones of X2 to X5 are joined to form a ring; and the ligand LA is complexed to Ir through the two indicated dash lines to form a 5-membered chelate ring. Organic light emitting devices, consumer products, formulations, and chemical structures containing the compounds are also disclosed.

Abstract: Provided are organometallic compounds having a structure of Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: The present disclosure provides a compound having a first ligand LA of Formula I, In Formula I, each of Z1, Z2, and X1 to X4 is C or N; moiety A is a monocyclic ring or a polycyclic fused ring system; moiety C is a monocyclic ring or a polycyclic fused ring system; K is selected from the group consisting of a direct bond, O, S, N(R?), P(R?), B(R?), C(R?)(R?), and Si(R?)(R?); Y is a linking group; each R, R?, R?, R?, R1, R2, and R3 is hydrogen or a General Substituent defined herein; wherein one of the statements as defined herein is true. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: The disclosure provides a compound having a Formula Ir(LA)x(LB)y(Lc)z or Ir(LA?)p(LB)q(Lc)r, wherein: LA has a structure of Formula IA ?LA? comprising a structure of Formula III: ?LB has a structure of Formula IB: ?LC is a bidentate ligand; and a structure of Formula II, ?is fused to at least one of moieties A, B, C, D, or ring H. Formulations, OLEDs, and consumer products containing the same are also provided.

Abstract: A compound of Formula Ir(LA)x(LB)y(LC)z is provided where x and y are independently 1 or 2; z is 0 or 1; and x+y+z=3; first ligand LA includes a structure of Formula I, ligand LB includes a structure of Formula II: and ligand LC is a bidentate ligand. In the compounds, moiety B is a polycyclic fused ring system comprising at least four rings; each of moiety C and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X4 and Z1 to Z6 is C or N; L0 is a direct bond or a linking group; YA is a linking group; each substituent is hydrogen or a General Substituent defined herein; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: The present disclosure provides compound having a first ligand LA, including those comprising a structure of Formula A, In the compound, each of X1P to X6P is C, N, or B, where at least one of X1P to X6P is N or B; at least four substituent pairs selected from (R1, R2), (R2, R3), (R3, R4), (R4, R5), (R5, R6), and (R6, R1) are joined or fused together to form rings fused to the center ring P; each of R1, R2, R3, R4, R5, and R6 is independently a hydrogen or a General Substituents defined herein; LA is coordinated to a metal M to form a 5-membered or 6-membered chelate ring; and any two substituents may be joined or fused to form a ring. Formulations, OLEDs, and consumer products containing such compounds are also provided.

Abstract: A compound having a first ligand LA including a structure of Formula I, is provided. In Formula I, each of moiety B and moiety D is a monocyclic ring or a polycyclic fused ring system; each of X1 to X5 is C or N; ring C is bonded to ring A by a C; K is a direct bond or a linking group; each RA, RB, RC, and RD is hydrogen or a General Substituent defined herein; at least one RC or RD comprises an electron-withdrawing group; and LA is coordinated to a metal M through the dashed lines. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound having a first ligand LA comprising a structure of Formula I, is provided. In Formula I, moiety A is a monocyclic ring or a polycyclic fused ring system; Z1 and Z2 are each C or N; each of Q1 to Q4 is C or N; K1 and K2 are each independently a direct bond or a linking group; two RA substituents are joined to form a structure of Formula II, fused to moiety A, wherein n is 0, 1, 2, or 3; two RB substituents are joined to form a cyclic moiety B1 fused to ring B; and each R?, R?, RA, RB, and RC is hydrogen or a General Substituent defined herein. Formulations, OLEDs, and consumer products containing the same are also provided.

Abstract: Novel metal complexes incorporating boron-containing aromatic compounds useful as a phosphorescent OLED material are disclosed.

Abstract: A compound comprising a ligand LA comprising a moiety L having a structure of Formula I is provided. In Formula I, LA coordinated to a metal M; A1 is selected from B, N, P, P?O, P?S, Al, Ga, SiR?, GeR?, and SnR?; where rings A, B, and C are 5- or 6-membered rings; Y1, Y2, and Y3 are selected from direct bonds, the metal M, and a variety of linkers; a+b+c=2 or 3; and one of a number of specific conditions is met. OLED devices, consumer products, and formulations including the compound are also provided.

Abstract: Novel Iridium complexes having three different bidentate ligands useful for phosphorescent emitters in OLEDs are disclosed. At least one of the three different bidentate ligands is a carbene ligand.

Abstract: A homoleptic or heteroleptic compound of Formula Ir(LA)x(LB)y(LC)z is provided where LA comprises a structure of Formula I, LB comprises a structure of Formula II, and LC comprises a structure of Formula III, In Formula I, Formula II, and Formula III, each of Z1 to Z12 is C or N; each of moiety A, and moiety C to moiety F is a monocyclic ring or a polycyclic fused ring system; at least one of RA to RF comprises a cyano-substituted alkyl; each RA to RF is hydrogen or a General Substituent defined herein; and at least one of the following is true: (1) moiety B is comprised of four or more fused rings; (2) moiety B is comprised of three fused rings, and at least one RA or RB is a cyclic group. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound including a first ligand LA of Formula I, is disclosed. In Formula I, ring B is a 5- or 6-membered ring; X1, X2, and X3 are each CRA or N; R is a 5- or 6-membered carbocyclic or heterocyclic ring, which can be further fused or substituted; and (1) when ring B is an unfused 6-membered ring, X1 and X2 are N, and X3 is C; and (2) when ring B is a fused 6-membered ring, ring B has the structure of Formula II, In this structure, the wavy line indicates the point of connection to ring A; Q1 to Q6 are each C or N; and, when proviso (2) applies, (I) at least one of X1, X2, and X3 is N; or (II) R is two or more fused or unfused 5- or 6-membered carbocyclic or heterocyclic rings, or (III) both.

Abstract: A compound including a first ligand LA of Formula I, is disclosed. In Formula I, ring B is a 5- or 6-membered ring; X1, X2, and X3 are each CRA or N; R is a 5- or 6-membered carbocyclic or heterocyclic ring, which can be further fused or substituted; and (1) when ring B is an unfused 6-membered ring, X1 and X2 are N, and X3 is C; and (2) when ring B is a fused 6-membered ring, ring B has the structure of Formula II, In this structure, the wavy line indicates the point of connection to ring A; Q1 to Q6 are each C or N; and, when proviso (2) applies, (I) at least one of X1, X2, and X3 is N; or (II) R is two or more fused or unfused 5- or 6-membered carbocyclic or heterocyclic rings, or (III) at least ring A or R is substituted with a partially or fully deuterated alkyl or partially or fully deuterated cycloalkyl group.

Abstract: A compound having a first ligand LA of Formula I is disclosed, where Z1 to Z4 are each independently C or N; at least one of Z1 to Z4 is N; and ring A is a structure of Formula II

Abstract: Provided are organometallic compounds that includes a ligand LA of Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.